• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Number of written Chemistry, Manufacturing, and Controls (CMC) reviews for New Drug Applications (NDAs) completed by ONDQA during the month (1)

Dictionary: New Drug Applications (NDA) are applications to request permission to market a drug product in the U.S. for a specific use. ONDQA reviews the Chemistry, manufacturing, and controls information submitted in the NDA to ensure product quality (i.e., identity, strength, quality, purity, and potency) as it relates to the safety and efficacy of the drug product. This measure includes all review associated the review of chemistry, manufacturing, and controls information submitted in NDAs prior to approval.

This measure has been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research.

Fiscal Year - 2011

Skip graphic and jump to text data

Oct 2010N/A43
Nov 2010N/A33
Dec 2010N/A63
Jan 2011N/A59
Feb 2011N/A48
Mar 2011N/A47
Apr 2011N/A57
May 2011N/A48
Jun 2011N/A60
Jul 2011N/A39
Aug 2011N/A48
Sep 2011N/A49

FY 2011 Total: 594


  • (1) Includes all initial quality assessment (IQA) reviews, primary reviews, summary and executive reviews.


Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.